Safety Data Sheets:
Publications and Congresses
The information in this section may include content beyond what is in the FDA-approved label. Because the FDA has not approved such content, no conclusions regarding safety or efficacy may be made. Providing this information should not be construed as recommendation for use of a Genentech product for unapproved uses. For FDA-approved products please consult the product’s full prescribing information for a complete discussion of risks and benefits of the product(s) for its approved indication(s).
Publications: The list of publications is not an exhaustive list of published materials on the product. The list of references by data topics is selected per evidence-based medicine criteria. To browse a full listing of published scientific literature:
Congresses: The list of congresses is a subset of Roche/Genentech posters and oral presentations for the product with data presented at scientific meetings in the recent 24 months. To browse full Roche/Genentech congress presentations and posters:
Showing 75 out of 75 results
-
20240717 Four-Year Outcomes of Faricimab in DME: First Time Safety and Efficacy Results from the RHONE-X Long-Term Extension Trial
Khanani A, Kotecha A, Harrell E, et al. Presented at the Annual meeting of the American Society of Retina Specialists July 17-20, 2024 in Stockholm, Sweden.Diabetic Macular Edema (DME)Supportive Studies -
20240701 Efficacy of Faricimab vs Aflibercept in Diabetic Macular Edema in the 20/50 or Worse Vision Subgroup in Phase 3 YOSEMITE/RHINE Trials
Zarbin M, Tabano D, Ahmed A, et al. Ophthalmology. July 2024 doi.org/10.1016/j.ophtha.2024.05.025.Diabetic Macular Edema (DME)Exploratory Analysis -
20240219 TENAYA and LUCERNE: 2-Year Results from the Phase 3 nAMD Trials of Faricimab with Treat-and-Extend Dosing in Year 2
Khanani AM, Kotecha A, Chang A, et al. Ophthalmology. Available online 19 February 2024. doi.org/10.1016/j.ophtha.2024.02.014Neovascular Age-Related Macular Degeneration (nAMD)Pivotal Trial(s) -
20240125 Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials
Tadayoni R, Paris LP, Danzig CJ, et al. Ophthalmology 2024. doi.org/10.1016/j.ophtha.2024.01.029.Macular Edema Following Retinal Vein Occlusion (RVO)Pivotal Trial(s) -
20231228 Faricimab Treat-and-Extend for Diabetic Macular Edema: 2-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials
Wong TY, Haskova Z, Asik K, et al. Ophthalmology. Available online 28 December 2023. doi.org/10.1016/j.ophtha.2023.12.026Diabetic Macular Edema (DME)Pivotal Trial(s) -
20230801 An Assessment of the Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trial Patients With nAMD
Zarbin M, Weng CY, Souverain A, et al. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting; April 23-27, 2023; New Orleans, LA, USANeovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20230801 Morph-Interpolation Visualizations of the Effect of Monthly Intravitreal Injections of Faricimab 6.0 mg in Patients With Diabetic Macular Edema From the BOULEVARD Trial
Yonekawa Y, Glittenberg C, Maunz A, et al. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting; April 23-27, 2023; New Orleans, LA, USADiabetic Macular Edema (DME)Supportive Studies -
20230801 Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 1-Year Results From China Subpopulation of Phase 3 RHINE Trial
Sun X, Li X, Han, M, et al. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting; April 23-27, 2023; New Orleans, LA, USADiabetic Macular Edema (DME)Pivotal Trial(s) -
20230801 Time to Retinal Fluid Control With Faricimab vs Aflibercept in Patients With DME in the Phase 3 YOSEMITE/RHINE Trials
Rachitskaya A, Gibson K, Mar F, et al. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting; April 23-27, 2023; New Orleans, LA, USADiabetic Macular Edema (DME)Exploratory Analysis -
20230801 Faricimab Personalized Treat-and-Extend–based Dosing Dynamics in Patients With DME
Pearce I, Lim JI, Chen S-J,et al. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting; April 23-27, 2023; New Orleans, LA, USADiabetic Macular Edema (DME)Exploratory Analysis -
20230801 Real-world Use of Faricimab to Treat nAMD Patients in the UK (FARWIDE Study)
Patel PJ, Talks J, De Salvo G, Lotery A, et al. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting; April 23-27, 2023; New Orleans, LA, USANeovascular Age-Related Macular Degeneration (nAMD)Real World Experience (RWE) -
20230801 Faricimab Reduces Macular Leakage vs Aflibercept in Patients With DME
Nudleman E, Goldberg R, Csaky K, et al. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting; April 23-27, 2023; New Orleans, LA, USADiabetic Macular Edema (DME)Exploratory Analysis -
20230801 Faricimab Causes Rapid and Sustained Intraocular Suppression of Ang-2 and VEGF-A for Up to 16 Weeks in nAMD and DME
Muni RH, Bogman K, Stoilov I, et al. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting; April 23-27, 2023; New Orleans, LA, USANeovascular Age-Related Macular Degeneration (nAMD)Diabetic Macular Edema (DME)Pharmacokinetics (PK) and Pharmacodynamics (PD) -
20230801 Faricimab Rapidly Improves Fluid Parameters in Patients with nAMD
London N, Querques G, Kotecha A, et al. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting; April 23-27, 2023; New Orleans, LA, USANeovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20230801 Early Treatment Patterns and Outcomes in Patients With Neovascular Age-Related Macular Degeneration Initiating Faricimab: The FARETINA-AMD Study
Leng T, Tabano D, Garmo V, et al. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting; April 23-27, 2023; New Orleans, LA, USANeovascular Age-Related Macular Degeneration (nAMD)Real World Experience (RWE) -
20230801 Impact of Faricimab vs Aflibercept on Epiretinal Membrane Formation Over 2 Years in Eyes with DME in the YOSEMITE/RHINE Phase 3 Trials
Jaffe GJ, Ogura Y, Deák G, et al. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting; April 23-27, 2023; New Orleans, LA, USADiabetic Macular Edema (DME)Exploratory Analysis -
20230801 Individualized Faricimab Dosing Up to Every 16 Weeks Maintains Robust Anatomic and Vision Outcomes Through 2 Years in nAMD
Chaudhary V, Kotecha A, Willis JR, et al. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting; April 23-27, 2023; New Orleans, LA, USANeovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20230801 Early Treatment Patterns and Outcomes in Patients with Diabetic Macular Edema Treated With Faricimab: The FARETINA-DME Study
Tabano D, Garmo V, Leng T, et al. Presented at the American Society of Retina Specialists Annual Meeting; July 28–August 1, 2023; Seattle, WA, USADiabetic Macular Edema (DME)Real World Experience (RWE) -
20230801 Real-world Use of Faricimabto Treat DME Patients in the UK (FARWIDE Study)
Gale RP, Peto T, Talks J, et al. Presented at the American Society of Retina Specialists Annual Meeting; July 28–August 1, 2023; Seattle, WA, USADiabetic Macular Edema (DME)Real World Experience (RWE) -
20230428 Individualized Faricimab Dosing up to Every 16 Weeks Maintains Robust Anatomic and Vision Outcomes Through 2 Years in nAMD
Chaudhary V, Kotecha A, Willis JR, et al. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting; April 23-27, 2023; New Orleans, LA, USANeovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20230428 Faster Time to Retinal Fluid Control With Faricimab vs Aflibercept in Patients With DME in the Phase 3 YOSEMITE/RHINE Trials
Pollreisz A, Camino A, Gibson K, et al. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting; April 23-27, 2023; New Orleans, LA, USADiabetic Macular Edema (DME)Exploratory Analysis -
20230428 Faricimab Reduces Macular Leakage vs Aflibercept in Patients With DME
Goldberg R, Kolomeyer AM, Nudleman E, et al. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting; April 23-27, 2023; New Orleans, LA, USADiabetic Macular Edema (DME)Exploratory Analysis -
20230428 Faricimab Rapidly Improves Fluid Parameters in Patients With nAMD
Querques G, London N, Kotecha A, et al. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting; April 23-27, 2023; New Orleans, LA, USANeovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20230428 Faricimab Causes Rapid and Sustained Intraocular Suppression of Ang-2 and VEGF-A for Up to 16 Weeks in nAMD and DME
Bogman K, Avery R, Stoilov I, et al. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting; April 23-27, 2023; New Orleans, LA, USANeovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20230428 Efficacy, Durability, and Safety of Faricimabin Diabetic Macular Edema (DME): 1-Year Results From China Subpopulation of Phase 3 RHINE Trial
Sun X, Li X, Han M, et al. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting; April 23-27, 2023; New Orleans, LA, USADiabetic Macular Edema (DME)Exploratory Analysis -
20230428 Durable Vision Gains and Greater Fluid Control With Extended Faricimab Dosing vs Aflibercept in Patients With DME
Lim JI, Chen SJ, Steinle NC, et al. Presented at the Association for Research in Vision and Ophthalmology Annual Meeting; April 23-27, 2023; New Orleans, LA, USADiabetic Macular Edema (DME)Exploratory Analysis -
20230411 Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial.
Mori R., Honda S, Gomi F. et al. Jpn J Ophthalmol 67, 301–310 (2023). https://doi.org/10.1007/s10384-023-00985-wNeovascular Age-Related Macular Degeneration (nAMD)Pivotal Trial(s) -
20230227 Durable Vision Gains and Greater Fluid Control With Extended Faricimab Dosing Up to Every 16 Weeks Over 2 Years of Phase 3 YOSEMITE and RHINE Trials in DME
Lai TYY, Wong TY, Jaffe GJ, et al. Presented at the Asia-Pacific Academy of Ophthalmology Congress; February 23-26, 2023; Kuala Lumpur, MalaysiaDiabetic Macular Edema (DME)Exploratory Analysis -
20230227 Faricimab in Neovascular Age-Related Macular Degeneration: Year 1 Results With Week 12 Fluid Data From the Phase 3 TENAYA and LUCERNE Trials
Cheung G, Guymer RH, Souverain A, et al. Presented at the Asia-Pacific Academy of Ophthalmology Congress; February 23-26, 2023; Kuala Lumpur, MalaysiaNeovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20230227 Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Patient Case Profiles From the Phase 3 TENAYA/LUCERNE Trials
Chen SJ, Koh AHC, Swaminathan B, et al. Presented at the Asia-Pacific Academy of Ophthalmology Congress; February 23-26, 2023; Kuala Lumpur, MalaysiaNeovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20230220 Clinical Outcomes of Diabetic Macular Edema Patients Treated With Faricimab and Aflibercept: A Subcohort Analysis of 20/50 or Worse Visual Acuity Across Faricimab Phase 3 Clinical Trials
Zarbin M, Ding A, Tabano D, et al. Presented at the Macula Society Annual Meeting; February 15-18, 2023; Miami, FL, USADiabetic Macular Edema (DME)Exploratory Analysis -
20230220 Durable Vision Gains and Greater Fluid Control With Extended Faricimab Dosing Up to Every 16-Weeks Over 2 Years of Phase 3 YOSEMITE and RHINE Trials in DME
Weng CY, Steinle NC, Goldberg RA, et al. Presented at the Macula Society Annual Meeting; February 15-18, 2023; Miami, FL, USADiabetic Macular Edema (DME)Exploratory Analysis -
20230220 Improved Retina Fluid Control With Faricimab vs Aflibercept in Phase 3 Trials in nAMD and DME
Dhoot D, Haskova Z, Ives J, et al. Presented at the Macula Society Annual Meeting; February 15-18, 2023; Miami, FL, USANeovascular Age-Related Macular Degeneration (nAMD)Diabetic Macular Edema (DME)Exploratory Analysis -
20230220 Individualized Faricimab Dosing up to Q16W Controls Anatomic Outcomes and Maintains Vision Through 2 Years in Age-Related Macular Degeneration (nAMD): Representative Case Studies
Bakri SJ, Pearce I, Figueroa MS, et al. Presented at the Macula Society Annual Meeting; February 15-18, 2023; Miami, FL, USANeovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20230212 Ang-2/VEGF Biology and Intraocular Suppression Following Intravitreal Administration of Faricimab
Csaky KG, Bogman K, Stoilov I, et al. Presented at the Angiogenesis, Exudation, and Degneration Virtual Congress; February 10-11, 2023; Miami, FL, USANeovascular Age-Related Macular Degeneration (nAMD)Diabetic Macular Edema (DME)Exploratory Analysis -
20221121 Efficacy, Durability and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Lai TYY, Haskova Z, Mohan S, et al. Presented at the Congress of the Asia-Pacific Vitreo-retina Society; November 18-20, 2022; Taipei Nangang, Taiwan.Diabetic Macular Edema (DME)Exploratory Analysis -
20221121 Intraocular Suppression of VEGF-A and Ang-2 Following Intravitreal Administration of Faricimab
Diack C, Avery RL, Stoilov I, et al. Presented at the Congress of the Asia-Pacific Vitreo-retina Society; November 18-20, 2022; Taipei Nangang, Taiwan.Neovascular Age-Related Macular Degeneration (nAMD)Diabetic Macular Edema (DME)Exploratory Analysis -
20221121 Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Cheung G, Holz FG, Khanani AM, et al. Presented at the Congress of the Asia-Pacific Vitreo-retina Society; November 18-20, 2022; Taipei Nangang, Taiwan.Neovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20221120 Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Results With Week 12 Fluid Data From the Phase 3 TENAYA and LUCERNE Trials
Guymer RH, Cheung G, Souverain A, et al. Presented at the Congress of the Asia-Pacific Vitreo-retina Society; November 18-20, 2022; Taipei Nangang, Taiwan.Neovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20221108 Clinical Outcomes of Diabetic Macular EdemaPatients Treated With Faricimab and Aflibercept: A Subcohort Analysis of 20/50 or Worse Visual Acuity Across FaricimabPhase 3 Clinical Trials
Zarbin M, Ding A, Tabano D, et al. Presented at The Professional Society for Health Economics and Outcomes Research Europe Conference; November 6-9, 2022; Vienna, Austria, EUDiabetic Macular Edema (DME)Exploratory Analysis -
20221107 Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE/RHINE Trials of Faricimab in Diabetic Macular Edema
Steinle NC, Jaffe GJ, Gerendas BS, et al. Presented at the Annual Scientific Meeting of the Retina Society; November 2-5, 2022; Pasadena, CA, USADiabetic Macular Edema (DME)Exploratory Analysis -
20221107 Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Patient Case Profiles From the Phase 3 TENAYA and LUCERNE Trials
London N, Pearce I, Figueroa MS, et al. Presented at the Annual Scientific Meeting of the Retina Society; November 2-5, 2022; Pasadena, CA, USANeovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20221107 Efficacy, Safety, and Durability of Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Results From the Phase 3 TENAYA and LUCERNE Trials
Lim JI, Silverman D, Swaminathan B, et al. Presented at the Annual Scientific Meeting of the Retina Society; November 2-5, 2022; Pasadena, CA, USANeovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20221107 Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Khurana RN, Wells JA, Baumal CR, et al. Presented at the Annual Scientific Meeting of the Retina Society; November 2-5, 2022; Pasadena, CA, USADiabetic Macular Edema (DME)Exploratory Analysis -
20221107 Overview of the Faricimab Safety Profile From Four Phase 3 Trials in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration Through 2 Years
Jaffe GJ, Kardatzke D, Kotecha A, et al. Presented at the Annual Scientific Meeting of the Retina Society; November 2-5, 2022; Pasadena, CA, USANeovascular Age-Related Macular Degeneration (nAMD)Diabetic Macular Edema (DME)Safety -
20221107 Intraocular Suppression of VEGF-A and Angiopoietin-2 Following Intravitreal Administration of Faricimab
Avery RL, Stoilov I, Bogman K, et al. Presented at the Annual Scientific Meeting of the Retina Society; November 2-5, 2022; Pasadena, CA, USANeovascular Age-Related Macular Degeneration (nAMD)Diabetic Macular Edema (DME)Exploratory Analysis -
20221004 Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Results From the Phase 3 TENAYA and LUCERNE Trials
Singh RP, Khanani AM, Demetriades AM, et al. Presented at the Annual Meeting of the American Association of Ophthalmology; September 30- October 3, 2022; Chicago, IL, USANeovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20221004 Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema(DME): 2-Year Results From YOSEMITE and RHINE
Baumal CR, Wells JA, Danzig CJ, et al. Presented at the Annual Meeting of the American Association of Ophthalmology; September 30- October 3, 2022; Chicago, IL, USADiabetic Macular Edema (DME)Exploratory Analysis -
20221004 Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Patient Case Profiles From the Phase 3 TENAYA and LUCERNE Trials
Pearce IA, Figueroa MS, Kotecha A, et al. Presented at the Annual Meeting of the American Association of Ophthalmology; September 30- October 3, 2022; Chicago, IL, USANeovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20221004 Angiopoietin-2 Signalingand Vascular Stability With Faricimab in Diabetic Macular Edema
Maturi RK, Csaky KG, Danzig CJ, et al. Presented at the Annual Meeting of the American Association of Ophthalmology; September 30- October 3, 2022; Chicago, IL, USADiabetic Macular Edema (DME)MOA and Development -
20221004 Treat-and-Extend–Based Personalized Treatment Interval (PTI) Dynamics in the YOSEMITE/RHINE Trials of Faricimab in DME
Goldberg RA, Jaffe GH, Gerendas BS, et al. Presented at the Annual Meeting of the American Association of Ophthalmology; September 30- October 3, 2022; Chicago, IL, USADiabetic Macular Edema (DME)Exploratory Analysis -
20221004 Faricimab in Neovascular Age-Related Macular Degeneration: 48-Week Results by Dosing Cohort in the TENAYA/LUCERNE Trials
Cheung G, Lai TYY, Michels S, et al. Presented at the Annual Meeting of the American Association of Ophthalmology; September 30- October 3, 2022; Chicago, IL, USANeovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20221004 Intraocular Suppression of VEGF-A and Ang-2 Following Intravitreal Administration of Faricimab
Avery RL, Stoilov I, Bogman K, et al. Presented at the Annual Meeting of the American Association of Ophthalmology; September 30- October 3, 2022; Chicago, IL, USANeovascular Age-Related Macular Degeneration (nAMD)Diabetic Macular Edema (DME)Exploratory Analysis -
20220913 Personalised Treatment Interval (PTI) Dosing Dynamics in the Phase 3 YOSEMITE/RHINE Trials of Faricimab in Diabetic Macular Edema
Tan CS, Jaffe GJ, Gerendas BS, et al. Presented at the World Ophthalmology Congress; September 9-12, 2022; VirtualDiabetic Macular Edema (DME)Exploratory Analysis -
20220913 Efficacy, Durability and Safety of Faricimab in Diabetic Macular Edema:2-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Murata T, Wells JA, Baumal CR, et al. Presented at the World Ophthalmology Congress; September 9-12, 2022; VirtualDiabetic Macular Edema (DME)Exploratory Analysis -
20220913 Faricimab in Neovascular Age-Related Macular Degeneration: 48-Week Results by Dosing Cohort in the Phase 3 TENAYA/LUCERNE Trials
Michels S, Cheung G, Lai TYY, et al. Presented at the World Ophthalmology Congress; September 9-12, 2022; VirtualNeovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20220913 Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Results From the Phase 3 TENAYA and LUCERNE Trials
Hwang D, Holz FG, Khanani AM, et al. Presented at the World Ophthalmology Congress; September 9-12, 2022; VirtualNeovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20220913 Faricimab in Neovascular Age-Related Macular Degeneration:Efficacy, Safety and Durability Through Week 48 in TENAYA and LUCERNE
Guymer RH, Cheung G, Margaron P, et al. Presented at the World Ophthalmology Congress; September 9-12, 2022; VirtualNeovascular Age-Related Macular Degeneration (nAMD)Pivotal Trial(s) -
20220905 Efficacy, Durability and Safety of Faricimab in Diabetic Macular Edema:2-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Schlottmann PG, Wells JA, Haskova Z, et al. Presented at the 22nd EURETINA Congress; September 1-4, 2022; Hamburg, Germany, EU.Diabetic Macular Edema (DME)Exploratory Analysis -
20220905 Faricimab in Neovascular Age-Related Macular Degeneration: 48-Week Results by Dosing Interval Cohort in the Phase 3 TENAYA/LUCERNE Trials
Lai TYY, Michels S, Demetriades AM, et al. Presented at the 22nd EURETINA Congress; September 1-4, 2022; Hamburg, Germany, EU.Neovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20220905 Personalised Treatment Interval (PTI) Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema
Korobelnik JF, Jaffe GJ, Gerendas BS, et al. Presented at the 22nd EURETINA Congress; September 1-4, 2022; Hamburg, Germany, EU.Diabetic Macular Edema (DME)Exploratory Analysis -
20220905 Angiopoietin-2 Signalling and Vascular Stability With Faricimab in Diabetic Macular Edema
Joussen AM, Willis JR, Haskova Z, et al. Presented at the 22nd EURETINA Congress; September 1-4, 2022; Hamburg, Germany, EU.Diabetic Macular Edema (DME)MOA and Development -
20220905 Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Holz FG, Khanani AM, Demetriades AM, et al. Presented at the 22nd EURETINA Congress; September 1-4, 2022; Hamburg, Germany, EU.Neovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20220905 Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Patient Case Profiles From the Phase 3 TENAYA and LUCERNE Trials
Figueroa MS, Pearce I, Demetriades AM, et al. Presented at the 22nd EURETINA Congress; September 1-4, 2022; Hamburg, Germany, EU.Neovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20220905 Faricimab in Neovascular Age-Related Macular Degeneration (nAMD):Efficacy, Safety, and Durability Through Week 48 in the Phase 3 TENAYA and LUCERNE Trials
Cheung G, Guymer RH, Demetriades AM, et al. Presented at the 22nd EURETINA Congress; September 1-4, 2022; Hamburg, Germany, EU.Neovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20220718 Personalized Treatment Interval (PTI) Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema
Kitchens JW, Baumal CR, Jaffe GJ, et al. Presented at the American Society of Retina Specialists Annual Meeting; July 18, 2022; New York, NY, USA.Diabetic Macular Edema (DME)Exploratory Analysis -
20220718 Faricimab in Neovascular Age-Related Macular Degeneration: Year 2 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Khanani AM, Demetriades AM, Kotecha A, et al. Presented at the American Society of Retina Specialists Annual Meeting; July 18, 2022; New York, NY, USA.Neovascular Age-Related Macular Degeneration (nAMD)Exploratory Analysis -
20220717 Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Eichenbaum DA, Wells JA, Lim JI, et al. Presented at the American Society of Retina Specialists Annual Meeting; July 18, 2022; New York, NY, USA.Diabetic Macular Edema (DME)Exploratory Analysis -
20220505 Faricimab in Neovascular Age-Related Macular Degeneration: Updated Week 48 Efficacy, Safety, and Durability in the Phase 3 TENAYA and LUCERNE Trials.
London N, Guymer R, Demetriades AM, et al. Presented at the Association for Research in Vision and Ophthalmology; May 5, 2022; Denver, CO, USA.Neovascular Age-Related Macular Degeneration (nAMD)Pivotal Trial(s) -
20220505 Efficacy, Durability, and Safety of Faricimab in Diabetic Macular Edema: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Lim JI, Wells JA, Eichenbaum DA, et al. Presented at the Association for Research in Vision and Ophthalmology; May 5, 2022; Denver, CO, USA.Diabetic Macular Edema (DME)Exploratory Analysis -
20220505 Personalized Treatment Interval (PTI) Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema
Baumal CR, Kitchens JW, Jaffe GJ, et al. Presented at the Association for Research in Vision and Ophthalmology; May 5, 2022; Denver, CO, USA.Diabetic Macular Edema (DME)Exploratory Analysis -
20220219 Efficacy, Durability, and Safety of Intravitreal Faricimab with Extended Dosing Up to Every 16 Weeks in Patients with Diabetic Macular Oedema (YOSEMITE and RHINE): Two Randomised, Double-Masked, Phase 3 Trials
Wykoff CC, Abreu F, Adamis AP, et al. Lancet. 2022;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6Diabetic Macular Edema (DME)Pivotal Trial(s) -
20220219 Efficacy, Durability, and Safety of Intravitreal Faricimab Up To Every 16 Weeks for Neovascular Age-Related Macular Degeneration (TENAYA and LUCENRNE): Two Randomized, Double-Masked, Phase 3 Non-Inferiority Trials
Heier JS, Khanani AM, Quezada Ruiz C, et al. Lancet. 2022;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1Neovascular Age-Related Macular Degeneration (nAMD)Pivotal Trial(s) -
20220214 Faricimab in Diabetic Macular Edema: Two-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Wells JA, Asik K, Haskova Z, et al. Presented at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Congress; February 14, 2022; Miami, FL, USADiabetic Macular Edema (DME)Exploratory Analysis -
20220214 Faricimab in Neovascular Age-Related Macular Degeneration: Updated Week 48 Results From the Phase 3 TENAYA and LUCERNE Trials
Guymer R, Demetriades AM, Quezada Ruiz C, et al. Presented at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Congress; February 14, 2022; Miami, FL, USANeovascular Age-Related Macular Degeneration (nAMD)Pivotal Trial(s)
Looking for more information?
Reach out to a Genentech Medical Science Liaison near you, or connect with the contact center.
Call Us: 1-800-821-8590 Hours: Monday-Friday, 5am-5pm PT